Eisai Receives Approval for a New Oral Jelly Formulation of Aricept for the Treatment of Alzheimer’s Disease in Japan

24-Jul-2009 - Japan

Eisai Co., Ltd. announced that the Company had received approval for a new oral jelly formulation of Aricept® (donepezil hydrochloride) for the treatment of Alzheimer’s disease from the Japanese Ministry of Health, Labour and Welfare. The new oral jelly formulation is easier for patients with Alzheimer’s disease who have difficulty swallowing to take and is the first treatment of its kind in the world.

Aricept® is an acetylcholinesterase inhibitor developed by Eisai, which works to increase levels of acetylcholine, a neurotransmitter, in the brain. It is the only approved treatment for Alzheimer’s disease in Japan, and is used in the treatment of patients with mild to severe forms of the disease.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances